The number of applications for BioLife Solutions’ biopreservation reagents continues to grow, and we are pleased to highlight these newest citations:
Habiel, D., Espindola, M., Coelho, A., & Hogaboam, C. Modeling Idiopathic Pulmonary Fibrosis in Humanized SCID Mice. The American Journal of Pathology 2018 Apr; 188(4): 891-903. doi: 10.1016/j.ajpath.2017.12.020
Habiel et. al. provided detailed methods for the creation of humanized models of Idiopathic Pulmonary Fibrosis (IPF) in nonobese diabetic (NOD) SCID IL2Rg-/- (NSG) mice. Explants from surgical lung biopsy samples were minced and mechanically dissociated. Red blood cells removed by lysis. Dissociated cells were frozen in CryoStor® CS10 for later use. Prior to use, the dissociated cells frozen in CS10 were thawed rapidly, and washed in serum-free medium prior to injection into NSG mice, alone, or combined 1:1 with PKH-26-labeled fibroblasts previously isolated from surgical lung biopsy samples.
Baradez, M., Biziato, D., Hassan, E., Marshall, D. Application of Raman Spectroscopy and Univariate Modelling As a Process Analytical Technology for Cell Therapy Bioprocessing. Med. 2018; 5(47), 1-14. doi:10.3389/fmed.2018.00047
Baradez et. al. applied Raman spectroscopy to real time monitoring for key markers of cell growth and metabolism modeled in a stirred tank bioreactor system producing an autologous T-cell immunotherapy. To prepare the inoculum for the stirred culture system, peripheral blood-derived CD4+ T-cells and CD8+ T-cells were isolated and cryopreserved in CryoStor®CS10. At time of inoculation, T-cells frozen in CS10 were thawed, washed and resuspended in growth media at a concentration of 1 x 106cells/mL.
Aijaz, A., Li, M., Smith, D., Khong, D., LeBlon, C., Fenton, O. S., Olabisi, R. M., Libutti, S., Tischfield, J., Maus, M. V., Deans, R., Barcia, R. N., Anderson, D. G., Ritz, J., Preti, R., Parekkadan, B. Biomanufacturing for clinically advanced cell therapies. Nature Biomedical Engineering 2018; 2(6), 362-376. doi:10.1038/s41551-018-0246-6
In the review article, Aijaz et. al. present cutting-edge bioprocessing technologies applicable to commercial-scale production of cell therapy products. Cryopreservation technologies are presented in the section titled “Preservation and supply-chain management.” The authors noted that non-standardized cryomedia usually differ between labs, may contain additives such as plasma or serum that are not sustainable, and introduce variability, which is difficult to control. CryoStor is cited as a DMSO-containing cryoprotectant frequently used in the manufacture of cell therapies.
BioLife’s solutions are off-the-shelf, defined, protein-free, serum-free, and manufactured according to current Good Manufacturing Practice (cGMP) from USP-grade or higher/multicompendial components. Make our solution, your solution!